GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

ApicHope Pharmaceutical Group Co 300723.SZ · CNY

Health Care · Shenzhen · 🇨🇳 China

Compare

29.43

-1.18%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About ApicHope Pharmaceutical Group Co

Its shares trade on Shenzhen under the ticker 300723.SZ. It has been listed since 16 November 2017. In the fiscal year to 31 December 2025, it reported revenue of CN¥932.3m and a net loss of CN¥337.8m. At that date it held total assets of CN¥4.04bn and shareholders' equity of CN¥1.37bn.

ApicHope Pharmaceutical Co., Ltd. engages in the research and development, production, and sales of chemical medicine, traditional Chinese medicine products, and biological vaccines. The company is headquartered in Guangzhou, Guangdong. The company went IPO on 2017-11-16. The firm has two types of products which are children's drugs and chronic disease drugs. The children's drugs are used for the treatment of colds, digestive anorexia, viral infections, children's eczema and other diseases, including clindamycin palmitate dispersible tablets and clindamycin palmitate granules. The chronic disease drugs include hepatocyte growth-promoting hormone for injection, aceglutamine for injection and adenosine cyclophosphate for injection, which are used for the treatment of severe viral hepatitis and cardiovascular and cerebrovascular diseases. The firm is also engaged in selling drugs for agents.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
16 Nov 2017
Employees
1,386
Website
gdyph.com ↗

Leadership

Pay as last reported

  • Mr. Hanxiong LiChairman of the Board, General Manager, since 2018CN¥653,600
  • Mr. Huixing ZhangChief Financial OfficerCN¥616,500
  • Mr. Mingyuan ZhangDeputy General Manager, Secretary of the Board
  • Ms. Dongling YangDeputy General Manager, Director, since 2021CN¥1.2m
  • Mr. Handong LiDirectorCN¥453,600
  • Mr. Xianhua HuIndependent Director
  • Mr. Kejian ZhangIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • The company employs 1,386 full-time staff members.
  • It operates in the health care sector within China.
  • It has been publicly traded since November 2017.

Weaknesses

  • The source description is explicitly treated as untrusted.
  • Specific financial data points are not provided.
  • Market share metrics are absent from the facts.

Opportunities

  • The firm sells drugs through agents.
  • It produces chemical medicine and biological vaccines.
  • It develops products for chronic disease treatment.

Threats

  • Regulatory changes in the pharmaceutical industry.
  • Competition from other health care providers.
  • Potential risks associated with untrusted source data.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.